Investors weighing exposure to the artificial intelligence infrastructure build-out often encounter two distinct paths: companies already monetizing AI compute, and companies still converting land and power into signed contracts. HIVE Digital Technologies (HIVE) and Keel Infrastructure (KEEL) sit on opposite sides of that divide. Both began as Bitcoin miners and both are now repositioning around AI and HPC (high-performance computing) data centers, which makes their relative performance a useful case study in execution versus potential. This stock comparison is most relevant to traders and long-term investors seeking to understand how market positioning, revenue visibility, and balance-sheet strength differ between two companies pursuing the same thematic shift. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
HIVE Digital Technologies builds and operates green-energy data centers across Canada, Sweden, Paraguay, and Bermuda. The company runs a dual-engine strategy, pairing Bitcoin mining with a growing AI/HPC arm known as BUZZ HPC. In recent weeks, the focus has shifted decisively toward the GPU (graphics processing unit) cloud business, which has stacked up multi-year contracts, including a roughly $220 million agreement with Bell Canada and Cohere and a five-year, approximately $350 million deal to deploy Nvidia Blackwell Ultra GPUs. Management reports BUZZ HPC's annualized revenue run rate near $180 million, approaching its stated $200 million target.
Despite this commercial progress, the stock has shown meaningful relative weakness in recent market activity, trading well below its 52-week high and down sharply over the trailing year. Sentiment has been pressured by financing-related dilution concerns, widening net losses tied to accelerated depreciation, and broader weakness in the crypto-adjacent complex. Analysts nonetheless maintain a predominantly positive consensus, while some firms have trimmed price targets on near-term execution risk. From what I see, the revenue visibility here stands out as a key differentiator.
KEEL Infrastructure, formerly Bitfarms, rebranded and redomiciled to the United States in 2026 as a digital infrastructure and energy company. It has fully wound down its Bitcoin mining operations and now owns a development pipeline of roughly 2.2 gigawatts (GW) across Pennsylvania, Washington State, and Québec, including the Panther Creek, Sharon, Moses Lake, and Sherbrooke sites. The company's stated model is to deliver powered shell and co-location facilities to hyperscalers and AI customers.
In recent weeks, KEEL has advanced permitting and announced partnerships, including a backup-power agreement with PowerSecure for its Moses Lake campus, and reported strong liquidity approaching $800 million. However, its AI revenue has not yet materialized, and reported revenue from continuing operations declined sharply year over year as legacy mining wound down, while operating losses remained significant. Insider buying by the CEO and a 120%-plus gain since the rebrand reflect optimism, but the shares have also experienced pronounced single-session swings on financing and valuation concerns.
The core contrast between these two names is realized revenue versus option value. HIVE has already signed and begun monetizing AI contracts, giving it a visible, growing revenue stream and a clearer path to cash flow, though it also carries financing costs and dilution risk. KEEL holds a larger, geographically diversified power portfolio with substantial liquidity, but its AI segment remains pre-revenue, leaving the stock more dependent on future lease execution and permitting outcomes.
On risk factors, HIVE retains meaningful exposure to Bitcoin price swings through its mining arm and has a higher beta, amplifying market moves. KEEL is less exposed to crypto after its exit but faces construction, financing, and tenant-signing risk across a capital-intensive build-out. In terms of momentum, HIVE's contracted-revenue traction has not yet translated into sustained share-price outperformance, while KEEL's stock has been more event-driven, reacting sharply to analyst actions and deal headlines. I’m watching this closely because the execution timelines will likely determine which path delivers more predictable results.
Based on observable factors, Tickeron's AI would likely favor HIVE in the current environment. Its combination of signed multi-year GPU cloud contracts, a reported annualized revenue run rate approaching $200 million, and a more advanced commercialization stage offers greater trend consistency and a more verifiable catalyst path than KEEL's largely unrealized pipeline. While KEEL holds compelling upside optionality through its power portfolio and liquidity, that value remains contingent on future leases and permits. This assessment is probabilistic rather than definitive, reflecting relative positioning, execution visibility, and risk-adjusted momentum rather than a guarantee of future performance.
When comparing setups like HIVE versus KEEL, I find it helpful to review how different automated strategies have performed in similar market conditions. Tickeron’s Trending AI Robots page offers a clear way to examine the platform’s top-performing bots by metrics such as win rates and drawdowns, giving a data-driven perspective on relative momentum without replacing individual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
On October 28, 2026, the Stochastic Oscillator for HIVE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In 54 of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +11.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIVE advanced for three days, in 213 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
HIVE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIVE as a result. In 67 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for HIVE turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 30 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
HIVE moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIVE crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for HIVE moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIVE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HIVE entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.972) is normal, around the industry mean (3.059). P/E Ratio (9.174) is within average values for comparable stocks, (6.833). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (8.748) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (16.899).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. HIVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of cloud networking and enterprise Wi-Fi solution
Industry InvestmentBanksBrokers